Abstract:The role of the bound peptide in alloreactive T-cell recognition is controversial, ranging from peptide-independent to peptide-specific recognition of alloreactive T-cells. The aim of this study is to find the evidence that there exist peptide/MHC complex (pMHC)-specific CTLs among alloreactive T cells generated with long-term mixed lymphocytes culture (LTMLC). A single pMHC was manipulated by loading the TAP-defective, HLA-A2 expressing T2 cells with a viral peptide (LMP2A426–434) or a self-peptide (Tyr369–377). The PBLs samples from 4 HLA-A2 positive (HLA-A2+ve) and 4 HLA-A2 negative (HLA-A2-ve) donors were included in this study. The HLA-A2+ve PBL co-cultured with the LMP2A426–434 pulsed T2 (T2/LMP) stands for the nominal T-cell response to a viral antigen, and the HLA-A2-ve PBLs co-cultured with the Tyr369–377 pulsed T2 (T2/Tyr) for alloreactive T-cell response to an allogeneic antigen. The specificity of the expanded CTLs after the LTMLC was detected by their specific cytotoxicity and binding ability to specific pMHC-tetramer. An HLA-A2 restricted, HIV peptide (Gag77–85) was included for control. The cultural bulk of HLA-A2+ve PBLs with the T2/LMP showed an elevated specific cytotoxicity against the T2/LMP compared to that against the T2/HIV (26.52%±3.72% vs 7.01%±0.87%, P<0.001), and an increased frequency of binding to LMP-tetramer compared to that binding to HIV-tetramer (0.98%±0.33% vs 0.05%±0.01%, P=0.0014). The cultural bulk of HLA-A2-ve PBLs with the T2/Tyr showed a more active cytotoxicity against the T2/Tyr than that against T2/HIV (28.07%±2.58% vs 6.87%±1.01%, P<0.001), and a higher frequency of binding to the Tyr-tetramer than that binding to the HIV-tetramer (0.88%±0.3% vs 0.06%±0.03%, P=0.0018). Our results indicate that the LTMLC is able to expand the viral antigen-specific CTLs as well as allogeneic antigen-specific CTLs. A relatively large proportion of alloreactive CTLs should be pMHC-specific, i.e., the specificity of the alloreactive lines depends on both the bound peptide and the allotype of MHC. Our observations support the hypothesis that the cumulative effect of T cells specific to each peptide epitope could account for the strength and diversity of the alloresponse. The method using manipulated pMHC and the LTMLC to generate pMHC-specific, alloreactive CTLs is of potential importance for adoptive T-cell immunotherapy.

Raising Allo-Restricted Cytotoxic T Lymphocytes by Co-Culture of Murine Splenocytes with Autologous Macrophage Bearing the Peptide/allo–major Histococompatibility Complex

Allo-Restricted Ctls Generated By Coculturing Of Pbls And Autologous Monocytes Loaded With Allogeneic Peptide/Hla/Igg1-Fc Fusion Protein

Peptide-Specific, Allogeneic T Cell Response in Vitro Induced by A Self-Peptide Binding to Hla-A2

In Vivo Anti-Melanoma Eycacy of Allo-Restricted CTLs Speciwc for Melanoma Expanded by Artiwcial Antigen-Presenting Cells

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

Peptide-dependent inhibition of alloreactive T-cell response by soluble divalent HLA-A2/IgG molecule in vitro.

Breaking tolerance with engineered class I antigen-presenting molecules

The Receptor for Hyaluronic Acid-Mediated Motility Induces Specific CD8+ T Cell Response in Healthy Donors and Patients with Chronic Myeloid Leukemia after Allogeneic Stem Cell Transplantation

Allogeneic Dendritic Cells Induce Potent Antitumor Immunity by Activating KLRG1+CD8 T Cells

Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.

Universal Protection of Allogeneic T-Cell Therapies from Natural Killer Cells via CD300a Agonism

Universal protection of allogeneic T cell therapies from natural killer cells vxia CD300a agonism

A strategy to reconstitute immunity without GVHD via adoptive allogeneic Tscm therapy

Viral Specific Cytotoxic T Cells Inhibit the Growth of TfR-expressing Tumor Cells with Antibody Targeted Viral Peptide/hla-A2 Complex

Stimulation of human EBV- and CMV-specific cytolytic effector function using allogeneic HLA molecules

Induction of tumor specific cytotoxic T lymphocytes from human peripheral blood by stimulation with MHC-I matched allogenic renal cell carcinoma

[Role of Alloreactive Natural Killer Cell in Mouse MHC Haploidentical Bone Marrow Transplantation].

Cytokine-induced Killer Cells Co-Cultured with Non-Cell Derived Targeting Peptide-Loaded Dendritic Cells Induce a Specific Antitumor Response.

Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen

Identification and analysis of alloreactive T lymphocytes from peripheral blood mononuclear cells

Semi-allogeneic Vaccine for T-cell Lymphoma